Peter Behner - 09 Mar 2022 Form 4 Insider Report for MiNK Therapeutics, Inc. (INKT)

Reporting relationship: Director
Issuer ticker: INKT
Reported as of: 09 Mar 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Mar 2022, 15:16:14 UTC
Prior SEC filing: 20 Oct 2021
Next SEC filing: 19 Sep 2022
Source filing: View source filing
Reporting owner signature: By: /s/ Christine Klaskin, Attorney-in-Fact

Key filing fact

Peter Behner filed Form 4 for MiNK Therapeutics, Inc. (INKT) on 11 Mar 2022.

Key facts

This page summarizes Peter Behner's Form 4 filing for MiNK Therapeutics, Inc. (INKT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 11 Mar 2022, 15:16.

Change

Previous filing in this sequence was filed on 20 Oct 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INKT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +15,000
Change %
Price: $0.000000
Shares after: 15,000
Date: 09 Mar 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,000
Exercise price: $2.89
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests in full on the one-year anniversary of the date of grant, provided that the Reporting Person continues to serve on the Issuer's Board of Directors through such date.